These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 28619423)

  • 1. Acute respiratory distress syndrome following alemtuzumab therapy for relapsing multiple sclerosis.
    Yann K; Jackson F; Sharaf N; Mihalova T; Talbot P; Rog D; Pace A
    Mult Scler Relat Disord; 2017 May; 14():1-3. PubMed ID: 28619423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pneumocystis pneumonia in a patient treated with alemtuzumab for relapsing multiple sclerosis.
    Lau AY; Lui GCY; Chan KP; Au C; Mok VCT; Ziemssen T
    Mult Scler Relat Disord; 2020 Feb; 38():101503. PubMed ID: 31743846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alemtuzumab in multiple sclerosis during the COVID-19 pandemic: A mild uncomplicated infection despite intense immunosuppression.
    Carandini T; Pietroboni AM; Sacchi L; De Riz MA; Pozzato M; Arighi A; Fumagalli GG; Martinelli Boneschi F; Galimberti D; Scarpini E
    Mult Scler; 2020 Sep; 26(10):1268-1269. PubMed ID: 32463329
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous CMV and
    Pappolla A; Midaglia L; Boix Rodríguez CP; Puig AA; Lung M; Camps IR; Castilló J; Mulero P; Vidal-Jordana A; Arrambide G; Rodriguez-Acevedo B; Sastre-Garriga J; Río J; Comabella M; Galán I; Tintoré M; Montalbán X
    Neurology; 2019 Feb; 92(6):296-298. PubMed ID: 30587519
    [No Abstract]   [Full Text] [Related]  

  • 5. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pneumonitis secondary to alemtuzumab in a patient with multiple sclerosis - A non-infectious cause of breathlessness.
    Whiteside D; Barth S; Datta A; Trip SA
    Mult Scler Relat Disord; 2018 May; 22():139-140. PubMed ID: 29684788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alemtuzumab-induced lung injury in multiple sclerosis: Learning from adversity in three patients.
    Bianco A; Mari PV; Larici AR; Lucchini M; Nociti V; Losavio FA; De Fino C; Cicchetti G; Coraci D; Richeldi L; Mirabella M
    Mult Scler Relat Disord; 2020 Jan; 37():101450. PubMed ID: 31675637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutropenia in Patients With Multiple Sclerosis Treated With Alemtuzumab.
    Gaitán MI; Ysrraelit MC; Correale J
    JAMA Neurol; 2017 Sep; 74(9):1143-1144. PubMed ID: 28715536
    [No Abstract]   [Full Text] [Related]  

  • 10. Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.
    Myro AZ; Bjerke G; Zarnovicky S; Holmøy T
    BMC Pharmacol Toxicol; 2018 Nov; 19(1):75. PubMed ID: 30454022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis.
    Buonomo AR; Saccà F; Zappulo E; De Zottis F; Lanzillo R; Gentile I; Carotenuto A; Borgia G; Russo CV
    Mult Scler Relat Disord; 2019 Jan; 27():44-45. PubMed ID: 30316174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute posterior multifocal placoid pigment epitheliopathy after alemtuzumab treatment for relapsing-remitting multiple sclerosis.
    Gao J; Jones J; Damato EM; Coles A
    J Neurol; 2019 Jun; 266(6):1539-1540. PubMed ID: 30895387
    [No Abstract]   [Full Text] [Related]  

  • 13. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
    Aitken L; Patel R; D'Rozario J; Choi P
    Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune-Mediated Hepatitis Induced by Therapy With Alemtuzumab in a Patient With Multiple Sclerosis.
    Bolte FJ; Schmidt HH; Schlevogt B
    Hepatology; 2021 Jan; 73(1):460-463. PubMed ID: 32583445
    [No Abstract]   [Full Text] [Related]  

  • 16. Alemtuzumab-associated diffuse alveolar damage - a case report.
    Bayas A; Menacher M; Schwaiblmair M; Märkl B; Naumann M
    BMC Neurol; 2020 Sep; 20(1):357. PubMed ID: 32967641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab.
    Barton J; Hardy TA; Riminton S; Reddel SW; Barnett Y; Coles A; Barnett MH
    Neurology; 2017 Mar; 88(10):1004-1006. PubMed ID: 28179462
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.
    Romba MC; Newsome SD; McArthur JC
    Mult Scler Relat Disord; 2019 Sep; 34():100-102. PubMed ID: 31252364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].
    Eichau S; Lopez-Ruiz R; Ruiz-Pena JL; Paramo MD; Navarro-Mascarell G; Izquierdo G
    Rev Neurol; 2018 Jun; 66(11):395-396. PubMed ID: 29790573
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New Warning for the Multiple Sclerosis Drug Alemtuzumab.
    Aschenbrenner DS
    Am J Nurs; 2019 Mar; 119(3):21. PubMed ID: 30801313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.